RSV

U.S. approved the RSVpreF vaccine for adults 60 years and older in 2023, recommending it only based on individual’s decisions with their doctors.

A new study highlighted the potential benefits of RSV vaccination, suggesting that the vaccines could provide both individual and societal cost savings.

Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations in those 60 and older.

The company's vaccine consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein.

Researchers in a new study found that the overall risk of RSV-related hospitalization for adults with inflammatory bowel disease was greatest for those who were 18 to 49 years of age and those who were 65 years of age or older.

The CDC has raised the recommded age at which people should get vaccinated to 75 and there are now three FDA-approved RSV vaccines

The results of an international study highlight the significant impact of the Arexvy vaccine in fostering robust immune responses.

According to the new recommendations, ACIP recommends that adults ages 75 years and older receive a single dose of RSV vaccine. It is a single-dose-per lifetime recommendation, so those who have already received a dose of RSV vaccine in the past are not recommended to receive an additional dose.

The FDA approved the expanded age indication for the RSV drug to ages 50 to 59 this past Friday, after initially being approved in the U.S. in May 2023 for RSV patients ages 60 and older.